Bayer-Monsanto Merger "Anti-competitive," Bad For Monsanto InvestorsMark Melin
The Bayer-Monsanto merger reveals truths about Monsanto and its product cycle that have led CLSA to downgrading the stock to “underperform” from buy. In a September 15 report, analyst Mark Connelly says the details of the proposed deal point to structural weakness inside Monsanto and their product cycle that should be of concern to investors – concerns that are not properly priced into the market. Yesterday former US Department of Justice officials expressed concern over the merger.
Worries over merger are justified on several . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.